Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1773Uterine Cervical Neoplasms 1499Endometrial Neoplasms 833Breast Neoplasms 434Carcinoma, Ovarian Epithelial 405Fallopian Tube Neoplasms 399Uterine Cervical Dysplasia 276Neoplasms 252Colorectal Neoplasms 179Uterine Neoplasms 173Peritoneal Neoplasms 170Vulvar Neoplasms 155Lung Neoplasms 150Pancreatic Neoplasms 141Prostatic Neoplasms 135Recurrence 128Stomach Neoplasms 126Colonic Neoplasms 116Papillomavirus Infections 115Melanoma 101Sarcoma 97Urinary Bladder Neoplasms 95Vaginal Neoplasms 93Carcinoma, Non-Small-Cell Lung 92Head and Neck Neoplasms 91Neoplasm Metastasis 83Esophageal Neoplasms 82Testicular Neoplasms 80Rectal Neoplasms 71Kidney Neoplasms 62

Interventions

defactinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Phase IB × Gynecologic × Clear all
NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

Data powered by HemOnc (CC BY 4.0) Colophon âš¡